Diabetes currently affects more than 62 million Indians, which is more than 7.1% of the adult population. The average age on onset is 42.5 years. Nearly 1 million Indians die due to diabetes every year.We have presence in Diabetes Therapy Area (TA) through our Diabetology & Metabolics Division. This reinforces our commitment to help patients manage their diabetes better and improve their Quality of Life (QoL). We have brands like Dapanorm, Dapanorm M, Euclide-XR, Euclide – M,Formin PG, Glucoryl-M, Glucoryl-MV, Gluvilda – M, Gluvilda OD, Olymprix M, Olymprix, Valera M, Valera, Voglikem, in diabetes therapy. We have exclusivity to market Evogliptin( Valera, Valera M) in India . Alkem’s commitment to fight diabetes has led it to launch Dapagliflozin (Dapanorm) and Dapanom M ( Dapagliflozin & Metformin fixed dose combination) in India .

Our aim is to be a key player in the Diabetes Therapy by providing affordable solutions to millions of diabetics across India.

Some of our key brands are: